DaVita Inc. (NYSE:DVA) Shares Sold by V Square Quantitative Management LLC

V Square Quantitative Management LLC lowered its holdings in DaVita Inc. (NYSE:DVA) by 18.8% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 2,049 shares of the company’s stock after selling 475 shares during the quarter. V Square Quantitative Management LLC’s holdings in DaVita were worth $284,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Newbridge Financial Services Group Inc. acquired a new stake in DaVita during the fourth quarter worth approximately $30,000. Versant Capital Management Inc lifted its position in DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after acquiring an additional 155 shares during the last quarter. Friedenthal Financial acquired a new position in DaVita in the second quarter valued at $48,000. Principal Securities Inc. purchased a new position in shares of DaVita during the fourth quarter worth about $37,000. Finally, GAMMA Investing LLC acquired a new stake in shares of DaVita during the fourth quarter worth about $60,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Trading Up 2.0 %

Shares of DaVita stock traded up $2.93 during trading hours on Wednesday, reaching $148.77. 636,149 shares of the company’s stock were exchanged, compared to its average volume of 836,121. DaVita Inc. has a 52-week low of $71.51 and a 52-week high of $151.05. The company has a fifty day moving average of $139.98 and a 200-day moving average of $134.26. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. The firm has a market capitalization of $13.05 billion, a price-to-earnings ratio of 16.91, a price-to-earnings-growth ratio of 0.81 and a beta of 0.87.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The business had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.15 billion. During the same period in the prior year, the firm posted $2.08 EPS. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. Sell-side analysts forecast that DaVita Inc. will post 9.9 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Barclays upped their price target on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Monday, May 6th. Bank of America raised their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. UBS Group increased their target price on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Truist Financial boosted their price target on DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $154.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.